证券代码：000813 证券简称：德展健康 公告编号：2024-021 德展大健康股份有限公司 2023 年年度股东大会决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 重要内容提示： 1、本次股东大会没有出现议案被否决的情形； 2、本次股东大会没有涉及变更以往股东大会决议的情形。 一、会议召开和出席情况 （一）会议召开情况 1、会议召开时间： 现场会议召开时间为 2024 年 5 月 8 日下午 14:30 分 网络投票时间为 2024 年 5 月 8 日 其中，通过深圳证券交易所交易系统进行网络投票的具体时间为：2024 年 5 月 8 日 9:15－9:25，9:30－11:30 和 13:00－15:00；通过深圳证券交易所互联网投 票系统投票的具体时间为：2024 年 5 月 8 日 9:15－15:00 期间的任意时间。 2、会议召开地点：新疆维吾尔自治区乌鲁木齐市水磨沟区昆仑东街 789 号 金融大厦 2110 会议室。 3、会议召开方式：本次股东大会采取现场投票与网络投票相结合的方式。 4、会议召集人：公司董事会。 5、现场会议主持人： ...

T&P 新疆天阳律师事务所 德展健康 2023 年年度股东大会 新疆天阳律师事务所 关于德展大健康股份有限公司 2023 年年度股东大会 法律意见书 天阳证股字[2024]第 10 号 新疆天阳律师事务所 二○二四年五月 1 天阳证股字[2024]第 10 号 致：德展大健康股份有限公司 新疆天阳律师事务所（下称本所）接受德展大健康股份有限公司（下称 公司）的委托，委派本所常娜娜律师、尹杰律师出席公司 2023 年年度股东大 会，根据《中华人民共和国公司法》（下称《公司法》）、《中华人民共和国 证券法》（下称《证券法》）、《上市公司股东大会规则》和《德展大健康股 份有限公司章程》（下称《公司章程》），按照律师行业公认的业务标准、 道德规范和勤勉尽责精神，对有关的文件和事实进行核查与验证，现出具法 律意见如下： 一、本次年度股东大会的召集、召开程序 1．公司董事会于 2024 年 4 月 12 日分别在《证券时报》《上海证券报》 《中国证券报》《证券日报》和巨潮资讯网站上刊登了《德展大健康股份有 限公司关于召开 2023 年年度股东大会通知》，该公告载明了本次年度股东 大会的届次、会议召集人、会议召开的合法合规 ...

Revenue and Profitability - Revenue for Q1 2024 was ¥101,250,441.65, a decrease of 25.09% compared to ¥135,160,087.88 in the same period last year[5] - Net loss attributable to shareholders was ¥16,805,072.84, representing a decline of 1,003.80% from a profit of ¥1,859,373.76 in Q1 2023[5] - The net loss for Q1 2024 was ¥21,613,891.55, a decline of 3,809.85% from a profit of ¥582,608.11 in Q1 2023[11] - The company reported a net loss of CNY 5,263,363.13 for Q1 2024, compared to a net loss of CNY 1,568,153.72 in Q1 2023[22] - Operating profit for Q1 2024 was -16,623,167.08 CNY, down from 7,656,637.23 CNY in the same period last year[23] - Total comprehensive income for Q1 2024 was -21,613,891.55 CNY, compared to 582,608.11 CNY in Q1 2023[24] Cash Flow - Cash flow from operating activities decreased by 54.43% to ¥22,723,297.27, down from ¥49,861,633.81 in the previous year[5] - The company experienced a 105.35% decrease in cash flow from investing activities, resulting in a net outflow of ¥20,673,911.95 compared to a net inflow of ¥386,383,653.20 in the previous year[11] - Cash flow from operating activities generated a net amount of 22,723,297.27 CNY, a decrease from 49,861,633.81 CNY in Q1 2023[24] - Cash flow from investing activities resulted in a net outflow of -20,673,911.95 CNY, compared to a net inflow of 386,383,653.20 CNY in the previous year[25] Assets and Liabilities - Total assets at the end of Q1 2024 were ¥5,357,834,623.56, a slight decrease of 0.39% from ¥5,378,612,557.62 at the end of 2023[5] - The company's total liabilities increased to CNY 150,877,373.16 from CNY 137,145,270.06 at the beginning of the year[20] - Non-current liabilities totaled CNY 37,948,349.21, down from CNY 39,942,766.26 at the beginning of the year[20] - The company’s equity attributable to shareholders was CNY 5,213,981,376.58, a decrease from CNY 5,237,902,679.94 at the beginning of the year[20] Shareholder Information - Total number of common shareholders at the end of the reporting period is 55,627[13] - The top 10 shareholders hold a combined 59.27% of the shares, with Shanghai Yueye holding 19.13% and Xinjiang Kaidi holding 18.93%[13] - Meilin Holdings Group has 14.57% of shares, which are currently frozen due to legal issues[15] - Meilin Holdings has been subject to judicial freezing of all its shares, totaling 315,379,600 shares, which is 100% of its holdings[15] Expenses and Income - Total operating costs for Q1 2024 were CNY 106,513,804.78, down 13.2% from CNY 122,728,241.60 year-over-year[22] - Sales expenses decreased by 35.18% to ¥16,885,140.89 from ¥26,048,241.63 in the same period last year[11] - Other income increased by 31.80% to ¥1,049,674.97, primarily due to an increase in government subsidies[11] - Research and development expenses for Q1 2024 were CNY 10,877,646.84, slightly down from CNY 11,907,421.27 in the same period last year[22] Future Expectations - The company expects a net profit attributable to shareholders of between RMB 61 million and RMB 90 million for the fiscal year 2023[15] - The net profit after deducting non-recurring gains and losses is expected to be a loss between RMB 50 million and RMB 95 million[15] Subsidiary Developments - The company completed the capital increase of its subsidiary, Meirui Wana Food and Beverage Co., Ltd., and obtained the new business license[15] - The company established a new subsidiary, Wuhan Weikang Medical Management Co., Ltd., with a total investment of CNY 50 million, where the company holds a 70% stake[16] - The company has completed the transfer of 51% equity of its wholly-owned subsidiary, Beijing Jialin Huikang Pharmaceutical Co., Ltd.[15] Share Capital - The company’s total share capital is 2,241,481,800 shares, with Meilin Holdings directly holding 448,263,156 shares, accounting for 20.00% of the total[15] - The company did not report any net profit from subsidiaries prior to the merger in the current or previous periods[24]

德展大健康股份有限公司 第八届监事会第十六次会议决议公告 证券代码：000813 证券简称：德展健康 公告编号：2024-019 本公司及其监事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 德展大健康股份有限公司（以下简称"公司"）第八届监事会第十六次会议的 通知已于 2024 年 4 月 21 日以电子邮件方式发出；公司于 2024 年 4 月 24 日 10:30 以通讯表决方式召开。应参加会议监事 5 人，实际参加会议监事 5 人。本次监事 会由监事会主席杨延超先生主持。本次会议的召集、召开符合《公司法》及《公司 章程》规定。 二、监事会会议审议情况 1、关于公司 2024 年第一季度报告的议案 公司依据生产经营情况编制了《2024 年第一季度报告》。 监事会审核意见：本报告期，公司监事会本着对全体股东负责的精神，对公司 2024 年第一季度报告进行了认真的审查，认为公司董事会编制和审议公司 2024 年 第一季度报告的程序符合法律、行政法规及中国证监会的规定，报告内容真实、准 确、完整地反映了上市公司的实际情况，不存在任何虚假记载、误导性 ...

证券代码：000813 证券简称：德展健康 公告编号：2024-018 德展大健康股份有限公司 第八届董事会第二十六次会议决议公告 本公司及其董事会全体成员保证信息披露内容的真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 1、德展大健康股份有限公司第八届董事会第二十六次会议决议。 特此公告。 德展大健康股份有限公司（以下简称"公司"）第八届董事会第二十六次会议 的通知已于 2024 年 4 月 21 日以电子邮件方式发出；公司于 2024 年 4 月 24 日 10:00 以通讯表决方式召开。应参加会议董事 9 人，实际参加会议董事 9 人。会议 由董事长魏哲明先生主持，公司全部监事及高管列席了本次会议。本次会议的召 集、召开符合《公司法》及《公司章程》的规定。 二、董事会会议审议情况 1、关于公司 2024 年第一季度报告的议案 公司依据生产经营情况编制了《2024 年第一季度报告》。 表决结果：同意 9 票，反对 0 票，弃权 0 票。 该议案审议获得通过。 具体内容详见同日在《证券时报》《上海证券报》《中国证券报》《证券日报》、 巨潮资讯网（http://www.cninfo.com.cn）披 ...

Company Overview - Dezhang Health reported no cash dividends, stock bonuses, or capital increases from reserves for the year 2023[3]. - The company underwent a significant business transformation in 2016, shifting from textile and mining industries to fully focus on the pharmaceutical sector by acquiring 100% equity of Jialin Pharmaceutical[18]. - The company’s stock is listed on the Shenzhen Stock Exchange under the code 000813[15]. - The registered address of Dezhang Health is located at Financial Building, No. 53 Jinyin Road, Tianshan District, Urumqi, Xinjiang, with a postal code of 830002[15]. - The company has a dual headquarters in Beijing and Urumqi, with the office in Beijing located at Bona Building, No. 2 Gongti East Road, Chaoyang District[15]. - The company’s website is www.dezhanhealthcare.com, providing access to financial reports and other investor information[15]. - The company’s legal representative is Wei Zheming, who is also responsible for the financial reporting accuracy[2]. Financial Performance - The company's operating revenue for 2023 was ¥498,088,171.28, a decrease of 12.75% compared to ¥570,855,435.18 in 2022[20]. - The net profit attributable to shareholders for 2023 was ¥83,314,246.81, representing a significant increase of 277.45% from a loss of ¥46,908,665 in 2022[20]. - The net cash flow from operating activities decreased by 20.93% to ¥127,872,780.78 in 2023, down from ¥161,719,681 in 2022[20]. - The total assets at the end of 2023 were ¥5,378,612,557.62, reflecting a decline of 5.24% from ¥5,674,395,997.63 at the end of 2022[21]. - The net assets attributable to shareholders decreased by 1.03% to ¥5,237,902,679.94 at the end of 2023, compared to ¥5,292,645,218.23 at the end of 2022[21]. - The basic earnings per share for 2023 was ¥0.0382, a turnaround from a loss of ¥0.0212 in 2022, marking an increase of 280.19%[20]. - The company reported a total of ¥150,080,266.75 in non-recurring gains for 2023, compared to ¥34,291,294.26 in 2022[26]. Market and Product Insights - The market size of lipid-regulating agents in China was approximately 22.5 billion yuan in 2022, with sales in public medical institutions exceeding 16.6 billion yuan, a year-on-year increase of 12.53%[31]. - Atorvastatin calcium tablets generated sales of 4.428 billion yuan in 2022, with a year-on-year growth of 7.45%[35]. - The sales of amlodipine atorvastatin calcium tablets increased by 18.42% in the first half of 2022[36]. - The company’s core products include atorvastatin calcium tablets and amlodipine atorvastatin calcium tablets, which are positioned as market leaders in their categories[37]. - The company has been deeply rooted in the Chinese lipid-lowering drug market for 20 years, successfully establishing the "Aler Quality" concept with its main product, Aler, which is the first generic version of the globally top-selling prescription drug Lipitor in China[51]. Research and Development - The company has established a technology R&D platform with approximately 200 high-educated professionals, accounting for about 20% of total employees, focusing on technology improvement and new drug development[52]. - The company is focusing on innovation in drug development, with resources being directed towards promising areas such as WYY and semaglutide[55]. - The company is advancing its innovative drug projects, including a neuroprotective agent for acute ischemic stroke, with key initial material trials underway[76]. - The company is expanding its product offerings with new biopharmaceuticals, including semaglutide for type II diabetes and collagen products for post-surgical recovery[77]. Strategic Initiatives - The company is actively exploring new business areas, including biopolypeptides and medical services, with products already launched in these segments[37]. - The company aims to reduce the premature mortality rate from cardiovascular diseases by 20% by 2025, as outlined in the national chronic disease prevention plan[45]. - The company has implemented strategies to enhance brand value and customer loyalty through training and promotional activities in collaboration with major retail chains[46]. - The company plans to enhance its market position by focusing on new product development and strategic acquisitions in the healthcare sector[112]. Governance and Management - The company has established a governance structure consisting of a shareholders' meeting, board of directors, supervisory board, and management team, ensuring effective operation and decision-making[129]. - The board of directors comprises 9 members, including 3 independent directors, and has established specialized committees to enhance governance and oversight[130]. - The company maintains independence from its controlling shareholder in terms of business operations, personnel, assets, organization, and finance, ensuring independent accounting and risk management[133]. - The company has a complete set of management systems covering financial, production, and sales processes, continuously improving according to legal requirements[131]. Sustainability and Corporate Responsibility - The management emphasized a commitment to sustainability, planning to invest 100 million RMB in eco-friendly initiatives over the next three years[147]. - The company is committed to enhancing investor protection through rigorous audit processes and compliance measures[165]. - The company has not faced any significant environmental protection issues as a key pollutant discharge unit[194]. Employee and Training Initiatives - The total number of employees at the end of the reporting period was 1,002, with 972 from major subsidiaries and 30 from the parent company[169]. - The company has implemented a salary policy based on "position determines salary, salary changes with position changes, and performance-based compensation"[170]. - A total of 24 training programs were conducted in 2023, covering various topics including GMP regulations, financial management, and safety training[171]. Future Outlook - Future performance guidance remains optimistic, with expectations for continued growth in revenue and market share[138]. - The company provided a positive outlook for the next fiscal year, projecting a revenue growth of 20% to 1.8 billion RMB[147]. - The company is exploring potential acquisitions to strengthen its market position, with a budget of 500 million RMB allocated for this purpose[147].

一、预算编制说明 公司根据 2023 年度的实际经营情况、财务状况和经营成果，结合 2024 年度生产 经营计划、投资计划，坚持战略引领、求实稳健、高质量发展等原则，按照《企业会 计准则》及其有关补充规定，将公司及其控制的所有子公司，均纳入预算编制范围， 编制 2024 年度财务预算。 二、基本假设 1、公司所遵循的国家和地方的现行有关法律、法规和制度无重大变化； 德展大健康股份有限公司 2024 年度财务预算报告 6、无其他不可抗力及不可预见因素对公司造成的重大不利影响。 三、主要预算指标 公司根据以前年度的财务指标，本着谨慎性原则，在充分考虑公司资产状况、经 营能力、生产经营计划等前提下，预计 2024 年度实现营业收入 5.53 亿元、归母净利 润 8,585 万元。 2024 年度，公司将积极开拓市场，提高市场占有率，强化成本费用管控，提升运 营效率，努力实现上述财务预算指标。 四、风险提示 公司 2024 年度财务预算指标不代表公司 2024 年度盈利预测，不构成公司对投资 者的实质性承诺，能否实现取决于市场状况、经营管理等多种因素。公司 2024 年度财 务预算存在一定的不确定性，提请广大投资者特 ...

证券代码：000813 证券简称：德展健康 公告编号：2024－016 德展大健康股份有限公司 关于 2023 年度计提资产减值准备的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 德展大健康股份有限公司（以下简称"公司"）根据《深圳证券交易所上市 公司自律监管指引第 1 号——主板上市公司规范运作》《企业会计准则》以及公 司相关会计政策的规定，对可能发生资产减值损失的资产计提减值准备。现将 具体情况公告如下： 一、本次计提减值准备情况概述 1、本次计提资产减值准备的原因 公司根据《企业会计准则》及公司内控管理的要求，公司对母公司及下属所 有子公司 2023 年末各类资产进行了全面清查盘点和分析，认为资产中应收票据、 应收账款、其他应收款、存货、无形资产存在一定的减值迹象。本着谨慎性原则， 公司需对可能发生资产减值的相关资产计提减值准备。 2、本次计提减值准备的资产范围、总金额、拟计入的报告期间 本次计提资产减值准备计入的报告期间为 2023 年 1 月 1 日至 2023 年 12 月 31 日。经过对 2023 年末存在可能发生减值迹象的资产进行清查 ...

----武滨 本人作为德展大健康股份有限公司（以下简称"公司""德展健康"）的独 立董事，2023 年，严格按照有关规定和要求，切实履行独立董事职责，积极出 席公司股东大会、董事会和董事会专门委员会会议，认真审议公司各项议案， 充分发挥独立董事作用，对公司的生产经营和业务发展积极提出合理的建议， 切实维护了公司整体利益和全体股东，尤其是中小股东的合法权益。 现将本人 2023 年度履职情况报告如下： 一、基本情况 本人于 1960 年 6 月出生，研究生学历，注册高级咨询师、执业药师。2012 年 4 月至 2020 年 7 月任中国医药商业协会常务副会长；2018 年 7 月至今先后担 任中国医药企业管理协会专家委员会委员，中国医药物资协会高级顾问。曾任瑞 康医药集团股份有限公司、广誉远中药股份有限公司、上海现代中医药股份有限 公司独立董事。现任老百姓大药房连锁股份有限公司、亚宝药业集团股份有限公 司、山东科源制药股份有限公司董事，哈药集团人民同泰医药股份有限公司、浙 江维康药业股份有限公司、山西振东制药股份有限公司以及德展健康独立董事。 作为公司的独立董事，本人未在公司担任除独立董事以外的任何职务，也未 ...

德展大健康股份有限公司 独立董事 2023 年度述职报告 ----孙卫红 作为德展大健康股份有限公司（以下简称"公司""德展健康"）的独立董事， 2023 年度本人严格按照《公司法》《证券法》等法律法规以及《公司章程》等的 有关规定，本着客观、公正、独立的原则，忠实、勤勉地履行独立董事的职责， 积极出席公司股东大会和董事会等相关会议，对公司的生产经营和业务发展提出 了合理的建议，较好发挥了独立董事的作用，切实维护了公司的整体利益，维护 了全体股东尤其是中小股东的合法权益。现将 2023 年度本人履行独立董事职责 情况汇报如下： 一、基本情况 本人于 1963 年 6 月生，大学学历，中国注册会计师、注册资产评估师、注 册税务师、高级会计师。历任乌鲁木齐市红山商场会计、财务科长、总经理助理； 1992 年加入驰远天合，现任新疆驰远天合有限责任会计师事务所董事长。曾任 新疆八一钢铁股份有限公司、新疆天康畜牧生物技术股份有限公司、里昂技术股 份有限公司独立董事。现任德展健康独立董事、特变电工股份有限公司独立董事。 2023 年任职期间，本人不在公司兼任除董事会专门委员会委员外的其他职 务，与公司及其控股股东不存在可 ...